Headlines about Relypsa (NASDAQ:RLYP) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Relypsa earned a coverage optimism score of 0.06 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.9783353182942 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/04/relypsa-rlyp-getting-somewhat-positive-media-coverage-study-finds.html.

Relypsa Company Profile

Relypsa, Inc is a United States-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of polymer-based medicines. The Company’s technology platform includes a high-throughput chemistry process, enabling the Company to explore various potential polymer medicines for each disease it seeks to address.

Insider Buying and Selling by Quarter for Relypsa (NASDAQ:RLYP)

Receive News & Stock Ratings for Relypsa Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relypsa Inc and related stocks with our FREE daily email newsletter.